MBD4

Across TCGA pan-cancer cohorts, MBD4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MBD4 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MBD4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MBD4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where MBD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.391	0.894	.001	35	view →
LSCC	OS	Median	III,IV	0.871	0.501	.015	8	view →
LUAD	OS	Quartile	All	1.000	0.637	.010	5	view →
HNSC	DFS	Tertile	III,IV	0.917	1.000	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MBD4–CCRCC (DFS)

Open the CCRCC breakdown →